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Abstract
Purpose Oral nutritional supplements (ONS) are com-
monly prescribed to malnourished patients to improve
their nutritional status. Taste and smell changes in pa-
tients with cancer can affect the palatability of ONS.
The present study investigated: (1) the palatability of
six ONS in testicular cancer patients before, during the
first two cycles, and after chemotherapy; (2) the relation
between the palatability and taste and smell function; (3)
the metallic taste of these ONS.
Methods Twenty-one testicular cancer patients undergoing
first-line cisplatin-based chemotherapy participated. Two milk-
based (vanilla; strawberry), two juice-based (apple; orange),
and two yoghurt-based (vanilla-lemon; peach-orange) ONS
were tested. A questionnaire was used to assess the palatability
of ONS and to which extent the attribute ‘metallic’ was appli-
cable. Taste and smell function were measured using taste
strips and ‘Sniffin’ Sticks’, respectively.
Results The palatability of ONS was highly variable among
patients. The milk-based strawberry ONS was preferred most
before, during, and after chemotherapy. The liking of the milk-
based vanilla ONS tended to decrease over time (p = 0.053),
whereas the liking of the other ONS remained stable. A higher
smell threshold and a lower sour taste threshold were corre-
lated to a decreased liking of the milk-based vanilla ONS. The
two juice-based ONS tended to taste more metallic during
than before chemotherapy.
Conclusion Health care professionals and patients should be
aware that the palatability of ONS can change over time.
Regular structured contact between health care professionals
and patients regarding the choice of ONS seems warranted.
Keywords Oral nutritional supplements . Taste . Smell .
Metallic . Cancer . Chemotherapy
Introduction
Malnutrition is a common problem in cancer patients with a
prevalence ranging from 30 to 85 % [1–3]. Oral nutritional
supplements (ONS) are commonly prescribed to malnour-
ished patients to improve their nutritional status [4]. ONS
can be used in addition to normal food consumption to in-
crease the nutrient intake. A variety of ONS is available, in-
cluding milk-, juice-, and yoghurt-based ONS in several fla-
vours. The hedonic evaluation of orosensory food cues under
standardized conditions, also referred to as palatability [5],
plays an important role in the acceptance of ONS [6–8].
Cancer patients undergoing chemotherapy often experi-
ence taste and smell changes [9–12]. These chemosensory
changes can affect the perceived flavour of ONS. Although
frequently prescribed, research regarding the palatability of
ONS in patients with cancer is limited. A study in 60 patients
with gastrointestinal cancer, of which 47 patients were
evaluable at follow-up, found no changes in preference for a
fresh milk-based, an ultra-high-temperature (UHT) milk-
based, and a fruit-based ONS after 5 weeks of chemotherapy
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compared to pre-chemotherapy [13]. Another study in 50 pa-
tients treated with pelvic radiotherapy (N = 38 at follow-up)
found no changes in preference for ONS varying in protein
source (elemental, peptide, and polymeric) after 6 weeks of
radiotherapy compared to pre-treatment [14]. The relation be-
tween taste and smell function and ONS preference was not
explored in those studies. Furthermore, the time between the
delivery of chemotherapy and study measurements was not
specified. This may be important, since differences in taste
function, appetite, and food liking can be apparent evenwithin
a chemotherapy cycle. A recent study in 52 breast cancer
patients treated with anthracycline and/or taxane based che-
motherapy showed a decrease in taste function, especially
during the first days of a chemotherapy cycle [10]. Changes
in taste, appetite, and food liking were cyclic and transient.
Therefore, measurements at one time point are unlikely to
reflect perception throughout the entire chemotherapy period.
This may also be the case for radiotherapy. However, to the
best of our knowledge, this has not been investigated system-
atically in a longitudinal study.
The relation between taste and smell changes in patients
with cancer and the palatability of ONS is currently unknown.
The relationship between taste function and the palatability of
ONS has been addressed by Kennedy et al. (2010) in 48
healthy older adults (63–85 years) compared to younger adults
(18–33 years) [15]. In that study [15] the detection and recog-
nition threshold for sweet taste, the perceived intensity of
sweetness, overall liking, and ranked preference of three types
of ONSwere explored. Although older adults had lower sweet
thresholds compared to young adults, no difference was found
in the perceived intensity of sweetness of the ONS [15].
However, a higher perceived sweetness was associated with
overall product dislike for all three ONS across both age
groups [15]. Whether a relationship exists between the taste
and smell function and the palatability of ONS in cancer pa-
tients needs to be explored.
A metallic taste is frequently reported by cancer patients
treated with chemotherapy with a prevalence ranging from 10
to 78 % [16]. The mechanism causing metallic taste is still
unknown. Metallic taste may be a specific taste alteration like
a change in threshold for sweet, sour, salty or bitter taste.
Moreover, metallic taste may be a combination of a gustatory
and olfactory sensation, implicating ‘metallic flavour’ would
be a better term for the experienced sensation. Metallic taste
may also be a particular bad taste in the mouth due to the taste
of chemotherapeutic agents. Whether certain types of ONS
elicit a metallic sensation and may thereby influence the ac-
ceptance of ONS in patients with cancer remains to be
elucidated.
The present study has the following objectives: (1) to in-
vestigate the palatability of six ONS (two milk-based, two
juice-based, and two yoghurt-based) in testicular cancer pa-
tients treated with cisplatin-based chemotherapy, (2) to
explore the relation between ONS palatability and the taste
and smell function of these patients, (3) to examine the metal-
lic taste of the ONS. Measurements were performed at five
time points: prior to chemotherapy, during the first cycle, be-
fore and during the second cycle, and 1 month after start of the
last cycle. Since taste and smell function and food liking can
vary throughout the chemotherapy treatment, we
hypothesised that by measuring the palatability of ONS at
multiple time points throughout the chemotherapy treatment,
changes in the palatability of ONS can be detected and that
changes in taste and smell function can influence the palat-
ability of ONS. Furthermore, we hypothesised that the attri-
bute of metallic taste varies between the ONS types (milk-
juice- or yoghurt-based) and can change within a treatment
period.
Materials and methods
Study population
Patients with disseminated testicular cancer scheduled to
receive first line cisplatin-based chemotherapy consisting
of bleomycin, etoposide and cisplatin (BEP) or
etoposide and cisplatin (EP) aged 18–50 years were el-
igible to participate in this study. Patients received three
or four cycles of chemotherapy with a cycle interval of
21 days. Inclusion criteria were: age 18–50 years at
start of treatment and ability to comprehend Dutch (both
reading and writing). Exclusion criteria were: mental
disability and co-morbidities affecting taste and/or smell
function, such as neurologic disorders, rhinosinusitis,
liver or renal problems, hyperactivity or hypoactivity
of the thyroid gland or diabetes. Patients had not re-
ceived other chemotherapy types or concurrent radio-
therapy prior to the present study. All patients gave
written informed consent. The study was approved by
the ethical committee of the University Medical Center
Groningen (NCT01641172).
Methods
The present study is part of a larger study regarding taste and
smell changes in testicular cancer patients. The taste and smell
function and the palatability of ONS were assessed at the
following time points: pre-chemotherapy (T0; baseline), dur-
ing the first cycle (T1; day seven of the first cycle), before the
second cycle (T2; day one of the second cycle prior to drug
administration), during the second cycle (T3; day seven of the
second cycle), and after chemotherapy (T4; 1 month after start
of the last cycle). Measurements were performed at the same
time of the day for all patients: late morning to early afternoon.
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The measurements were conducted in the same order for all
patients: (1) smell test, (2) taste test, (3) palatability ONS. At
baseline, data on height, smoking status, educational level,
and sports level were collected during a structured interview.
A digital scale was used to measure bodyweight in light cloth-
ing, without shoes. Body mass index (BMI) was calculated as
weight (kg) divided by the square of height (m2). Data
concerning disease and treatment were derived from medical
records.
Oral nutritional supplements
To study the effect of chemotherapy on the pleasantness of ONS
regarding type and flavour, a variety of ONS was selected. Six
ONS (Nutricia Advanced Medical Nutrition—Danone) were
tested: two high protein milk-based (vanilla and strawberry),
two juice-based (apple and orange), and two yoghurt-based
(vanilla-lemon and peach-orange) ONS. All ONS had a
energy density of 150 kcal/100ml. The nutrient content varied
between the three ONS categories (Online Resource 1).
Procedure
The ONS were served in 30 ml clear plastic tubs at cold temper-
ature. The patients were asked to take at least one sip of each
sample. Next, patients had to fill out a questionnaire regarding
the palatability and sensory attributes of the ONS on a seven-
point scale (Online Resource 2). The questionnaire comprised
nine closed questions regarding the palatability, 16 attributes,
and two open questions. The following two questions were used
from this questionnaire regarding the palatability and metallic
taste of ONS: BHowmuch do you like the taste of this product?^
(1 = dislike very much, 7 = like very much) and BPlease, specify
to which extent ‘metallic’ is applicable to the product^
(1 = strongly disagree, 7 = strongly agree). The patients
received a warming-up sample (semi-skimmed milk) and
completed the questionnaire to get used to the proce-
dure. The ONS were presented in randomized order
among patients and test sessions. All samples were la-
belled with a three-digit-code, varying over test sessions
to avoid recognition bias by numbers. Patients were
blinded to which ONS was being served. Patients rinsed
their mouth with water after each sample.
Taste and smell function
Filter-paper taste strips (Burghart, Wedel, Germany)
were used to measure recognition thresholds for sweet,
sour, salty, and bitter taste [17]. The patients were re-
quested not to smoke, brush teeth, use chewing gum or
to eat or drink with the exception of water 1 h prior to
the measurement. The following standard concentrations
of each taste were used: sweet: 0.05, 0.1, 0.2, and
0.4 g/ml sucrose; sour: 0.05, 0.09, 0.165, and 0.3 g/ml
citric acid; salty: 0.016, 0.04, 0.1, and 0.25 g/ml sodium
chloride; bitter: 0.0004, 0.0009, 0.0024, and 0.006 g/ml
quinine hydrochloride. The taste strips were placed in
the middle of the tongue for whole mouth testing. The
taste strips were presented in increasing concentrations
in a randomized order. Patients had to choose one of five
possible answers (sweet, sour, salty, bitter or no taste). Patients
rinsed their mouth with water after each taste strip. Scores for
each taste range from 0 (no concentrations correctly identified)
to 4 (all concentrations correctly identified). A total taste score
(range 0–16) was derived by summing the scores for all tastes.
‘Sniffin’ Sticks’ (Burghart, Wedel, Germany) were used to
measure the smell function [18, 19]. In brief, this test consists
of pen-like odour dispensing devices and includes three parts:
a threshold (THR) test, a discrimination (DIS) test, and an
identification (ID) test. The pens were presented approximate-
ly 2 cm under the middle of the nose. To measure the THR, a
standard series of pens with 16 dilutions of n-butanol was
used. Three pens were presented in a randomized order, one
contained the odorant and two solvent. The patients had to
identify the pen containing the odorant in two successive tri-
als, which triggered a reversal of the staircase. The THR was
defined as the mean of the last four reversals. For the DIS test,
16 triplets (two equal and one different odorant) were present-
ed. The patients had to discriminate which of the three pens
smelled differently. For the ID test, 16 common odours were
presented and the patients had to identify the odour using a
multiple choice task presented on a list of four different odor-
ants. For the THR and DIS test, there was a 30-s interval
between the presentation of the first pen of a triplet and the
presentation of the first pen of the following triplet. The pens
for the ID test and the taste strips were presented at a 30-s
interval. The patients were requested not to smoke, brush
teeth, use chewing gum or to eat or drink with the exception
of water 15 min prior to the measurement. The THR score
ranges from 1 to 16. The DIS and ID scores range from 0 to
16. A total smell score was derived by summing the THR, DIS
and ID, resulting in a threshold, discrimination, identification
(TDI) score (range 1–48). The extended version of the
‘Sniffin’ Sticks’ was used, containing 32 odour combinations
for the DIS test and 32 odours for the ID test [20]. Each patient
received a unique combination of 16 out of 32 triplets for the
DIS test, and a unique combination of 16 out of 32 pens for the
ID test.
Metallic taste
Two aspects of metallic taste were addressed. Patients had to
report to which extent metallic was applicable to the ONS.
Furthermore, patients had to report whether they experienced
a metallic taste as a side effect of chemotherapy. To examine
this second aspect, patients were asked to respond to the
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following open-ended questions regarding their subjective
taste perception since the start of treatment: BHave you expe-
rienced a change in taste?^ and BHave you experienced certain
foods to taste differently?^. In addition, patients had to
report how often they experienced a continuous bad
taste in their mouth (never, rarely, sometimes, often or
always) and patients had to describe the experienced
taste with the following response options Bsweet, sour,
salty, bitter or other namely .^ Patients were classified as
experiencing a metallic taste, when they reported a me-
tallic taste as a change in taste or as a bad taste in the
mouth. By exploring both aspects of metallic taste, in-
vestigation whether especially the patients who experi-
enced a metallic taste as a side effect of chemotherapy
reported that metallic taste was applicable to ONS could
be performed. Moreover, this enables investigation
whether a metallic taste is applicable for specific types
of ONS in cancer patients.
Statistical analysis
Descriptive statistics are presented as median with inter-
quartile range (IQR) or percentage. Possible differences
in palatability and metallic taste between the ONS per
test session were investigated using the Friedman test,
followed by the post-hoc related-samples Wilcoxon
signed-rank test. A linear mixed model was used to
investigate taste and smell function and the liking and
metallic taste of each ONS separately, over time. An
unstructured covariance type was used to model the covariance
structure among repeated measures. For ONS showing a signif-
icant change or a trend towards significance in liking or metal-
lic taste over time, possible differences in liking and metallic
taste were compared to baseline and possible differences during
the second cycle were explored. Test session was entered as
fixed effect in the model (T0 as baseline). Contrast compari-
sons were carried out to explore possible differences during the
second cycle (T2 versus T3). All models were estimated
using maximum likelihood. Spearman’s rho correla-
tion (rs) was used to investigate the relation between
taste and smell function and the liking of each ONS
over all test sessions. For ONS showing a significant
change in liking compared to baseline, spearman’s rho
correlation was used to explore the relation between
changes in taste and smell function and the change in
liking compared to baseline. For taste and smell pa-
rameters without a change over time (i.e. all parame-
ters, except salty taste), the mean of the taste and
smell parameters over all test sessions was used for
correlations (instead of the change over time of these
parameters). Spearman’s rho correlation was used to
explore the correlation between overall liking and me-
tallic taste of ONS over all test sessions, across all
ONS and per ONS separately. The Mann-Whitney U
test was used to compare the scores to which extent
‘metallic’ was applicable for each ONS with respect to
presence of metallic taste in patients. For this end, the
highest rating reported by each patient during test sessions in
which patients reported a metallic taste (T3 and T4) was
used. Patients with missing data on a variable relevant for a
specific analysis were excluded (indicated in tables). Given the
exploratory nature of the study, no adjustments were made for
multiple comparisons. A two-tailed p value of less than 0.05
was considered statistically significant. Statistical analyses were
performed using SPSS, version 22 (SPSS Inc. Chicago, IL).
Results
Characteristics of the study population
Twenty-eight patients were asked to participate. Twenty-one pa-
tients were enrolled in the study. Reasons for not participating
were: study too time consuming (n = 2) or unknown reasons
(n = 5). The baseline characteristics of the patients are shown
in Table 1. Four patients stopped their participation prematurely
(after T0: N = 2, after T1: N = 1, after T3: N = 1). Three patients
completed four out of five measurements due to illness during
chemotherapy (T1: N = 1, T3: N = 2).
Palatability of ONS
Table 2 shows the liking scores of eachONS per test session. The
liking of the milk-based vanilla ONS tended to decrease over
time (p = 0.053), whereas the liking of the other ONS remained
stable. The liking of the milk-based vanilla ONS decreased be-
fore and during the second cycle and after chemotherapy com-
pared to baseline (T2: p = 0.025; T3: p = 0.008; T4: p = 0.030).
See Online Resource 3 for estimates of fixed effects. No differ-
ence in liking of the milk-based strawberry ONS was found
compared to baseline. Figure 1 shows the liking scores of the
milk-based vanilla and strawberry over time. Awide variation in
ONS liking was found among patients (see Online Resource 4
for difference in liking compared to baseline). A difference in
liking between the ONS was found prior to chemotherapy
(T0, p = 0.019), during the first cycle (T1, p = 0.001),
and after chemotherapy (T4, p < 0.001). Patients pre-
ferred the milk-based strawberry ONS during all test
sessions. The liking of this ONS was significantly
higher than the juice-based orange (p = 0.010) and the
yoghurt-based vanilla-lemon (p = 0.021) ONS prior to
chemotherapy (T0) and higher than all other ONS dur-
ing the first cycle (T1) and after chemotherapy (T4)
(p < 0.05). See Online Resource 5 for the ranked pref-
erence based on liking scores of the ONS per test
session.
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Taste and smell function and the palatability of ONS
The threshold for salty taste increased after chemotherapy
(T4) compared to baseline (median (IQR); T0: 3 (3–3) and
T4: 2 (2–3); p = 0.006). No changes in the other primary tastes
or in smell function were found in patients compared to base-
line (data not shown).
A higher threshold for sweet and sour taste was correlated
with a higher liking of the milk-based strawberry ONS (sweet:
rs = −0.23, p = 0.026; sour: rs = −0.32, p = 0.002). A higher
threshold for sour taste was correlated with a higher liking of
the juice-based orange ONS (rs = −0.21, p = 0.044). A lower
threshold for sweet and bitter taste was correlated with a
higher liking of the yoghurt-based peach-orange ONS (sweet:
rs = 0.22, p = 0.040; bitter: rs = 0.29, p = 0.006). No significant
correlations were found between the salty taste threshold and
the liking of ONS.
A lower threshold for sour taste was correlated with a de-
creased liking of this ONS before the second cycle (T2) and
after chemotherapy (T4) compared to baseline (T2–T0:
rs = −0.57, p = 0.026; T4–T0: rs = −0.53, p = 0.043). No
significant correlations were found between the liking of
ONS and the smell DIS and ID.
A higher smell threshold was correlated to a lower liking of
the milk-based vanilla ONS over all time points (rs = 0.23,
p = 0.030), the juice-based orange ONS (rs = 0.21, p = 0.043),
and the yoghurt-based vanilla-lemon and peach-orange ONS
(rs = 0.24, p = 0.021 and rs = 0.25, p = 0.017, respectively).
A higher smell threshold was correlated with a decrease in
liking of the milk-based vanilla during the first cycle (T1)
compared to baseline (rs = 0.65, p = 0.006).
Metallic taste and the palatability of ONS
Table 3 shows the scores to which extent ‘metallic’ was ap-
plicable for each ONS per test session. No difference was
found regarding this attribute between the ONS per test ses-
sion. Overall, metallic taste of ONS was associated with a
lower liking of ONS (rs = −0.34, p < 0.001). Metallic taste
was also associated with a lower liking per ONS separately:
Table 1 Baseline characteristics of patients
Patients (N = 21)
Age (years), median (IQR) 32 (27–36)
Body weight (kg) median (IQR) 82.9 (74.4–91.6)
Height (m) median (IQR) 1.82 (1.78–1.90)
BMI (kg/m2) median (IQR) 24.3 (22.2–26.4)
Smoking, N (%)
No 12 (57)
Yes 4 (19)
Ex 5 (24)
Sports level, N (%)
Never 7 (33)
1–2 times/week 3 (14)
3 or more times/week 11 (52)
Educational level (range 1–7)a, median (IQR) 4 (4–6)
Chemotherapy regime, N (%)
BEP 17 (81)
EP 1 (5)
BEP/VIP 3 (14)
Number of chemotherapy courses, N (%)
3 15 (71)
4 6 (29)
Type of cancer, N (%)
Seminoma 9 (43)
Non-seminoma 12 (57)
IQR interquartile range; BEP bleomycin, etoposide and cisplatin; EP
etoposide and cisplatin; VIP etopside, ifosfamide and cisplatin
a Highest completed educational level: range 1 (primary school)–7
(university)
Table 2 Median (IQR) liking score of each ONS per test session (1 = dislike very much, 7 = like very much)
Pre-CT (baseline)
T0 (N = 21)
During first
cycle T1
(N = 18)
Before second
cycle T2
(N = 18)
During second
cycle T3 (N = 16)
1 month after
start last cycle
T4 (N = 17)
p value
Milk-based Vanilla 5 (3–6) 4 (2–5) 4 (2–5)* 3 (1–5)** 3 (3–5)* 0.053
Milk-based Strawberry 5 (3–6) 6 (5–6) 5 (3–6) 5 (3–6) 5 (4–6) 0.008a
Juice-based Apple 5 (3–5) 4 (3–5) 4 (3–5) 4 (3–6) 5 (3–6) 0.151
Juice-based Orange 4 (3–5) 3 (2–4) 3 (3–5) 5 (2–5) 4 (3–6) 0.587
Yoghurt-based Vanilla-Lemon 3 (2–5) 3 (2–5) 4 (2–5) 3 (2–6) 3 (2–5) 0.379
Yoghurt-based Peach-Orange 4 (3–6) 3 (2–5) 4 (3–5) 4 (3–6) 3 (2–5) 0.262
P values display differences in liking at each time point compared to baseline. The last column represents the main effect of time (p value of fixed effect)
IQR interquartile range
*p < 0.05; **p < 0.01
a Indicating difference between T1 and T2 (no difference in liking compared to baseline)
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milk-based vanilla: rs = −0.29, p = 0.005); milk-based straw-
berry: rs = −0.26, p = 0.013; juice-based apple: rs = −0.36,
p < 0.001; juice-based orange: rs = −0.53, p < 0.001; yoghurt-
based vanilla-lemon: rs = −0.26, p = 0.013; yoghurt-based
peach-orange: rs = −0.20, p = 0.064).
The metallic taste of the juice-based apple ONS increased
over time (p = 0.037) (Table 3). The metallic taste of this ONS
increased during the first cycle (T1) and after chemo-
therapy (T4) compared to baseline (p = 0.019 and
p = 0.006, respectively). An increased trend for metallic
taste of the juice-based orange ONS was found
(p = 0.056). The metallic taste of this ONS increased
before the second cycle (T2) and after chemotherapy
(T4) compared to baseline (p = 0.005 and p = 0.045,
respectively). See Online Resource 3 for estimates of
fixed effects.
Five of 21 patients (24%) reported a metallic taste. Three of
these patients experienced a metallic taste during the second
cycle (T3) and two patients reported metallic taste after che-
motherapy (T4). The score to which extent ‘metallic’ was
applicable for each ONS was higher for patients experiencing
a metallic taste compared to patients who did not experience a
metallic taste (median score of 6 versus 5, p = 0.035).
Discussion
The present study examined for the first time the palatability
of several ONS types and flavours at multiple time points
during treatment. In line with previous studies which mea-
sured the palatability only at one time point during treatment
[13, 14], no effect of treatment was found for the palatability
of five out of six ONS, suggesting that preference for most
types and flavours of ONS remain stable over time.
The palatability of the milk-based vanilla ONS tended to
decrease over time, whereas the high liking of the milk-based
strawberry ONS remained stable. The flavour, rather than the
nutrient content, played a role in the decreased preference of
the milk-based vanilla ONS, since the macro- and micronutri-
ent content of these two ONS were identical. Moreover, the
taste and smell function of patients with cancer may have
played a role, since a higher smell threshold and a lower sour
taste threshold were associated with a decreased liking of the
milk-based vanilla ONS.
Patients preferred the milk-based strawberry ONS be-
fore, during, and after chemotherapy over the other five
ONS. Other studies have also shown a preference for
milk-based over juice-based ONS in patients with can-
cer [13] and in a heterogeneous group of malnourished
patients [21]. Nevertheless, a wide variation in pleasant-
ness was found among patients. Therefore, a variety of
ONS types and flavours should be offered to patients,
so they can choose the product they like most. The
pleasantness of the milk-based vanilla ONS tended to
decrease over time. As a consequence, health care pro-
fessionals should inform patients that the palatability of
ONS can change over time and regular structured con-
tact between health care professionals and patients re-
garding the choice of ONS is warranted.
The metallic taste of both juice-based ONS tended to in-
crease during chemotherapy. These results suggest that juice-
based ONS are the least suitable ONS for patients experienc-
ing a metallic taste, which has a high prevalence in cancer
patients treated with chemotherapy [16]. Patients were not
specifically asked whether they experienced a metallic taste
during the present study. Nevertheless, approximately 25% of
the patients reported metallic taste using a questionnaire in-
cluding a question regarding the description of the experi-
enced taste alteration (sweet, sour, salty, bitter or Bother
Fig. 1 Liking score over time of a milk-based vanilla and b milk-based
strawberry ONS. *p < 0.05; **p < 0.01
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namely^). The patients reported ‘metallic’ using this alterna-
tive response option. Future studies with larger sample size
including the investigation of the mechanism of metallic taste
are needed to explore the relation between metallic taste ex-
perienced by patients with cancer and the metallic taste of
ONS in more detail. More detailed information may improve
the palatability of ONS for patients who experience a metallic
taste.
Strengths of the present study are the longitudinal design
including multiple time points during chemotherapy and the
homogeneous study population regarding type of cancer and
treatment, and treatment phase. A limitation is that no conclu-
sion can be drawn regarding the compliance to ONS, since
only the palatability of the ONS was assessed. Furthermore,
the threshold of umami taste was not investigated. The umami
taste may be relevant, since this is linked to the enjoyment of
protein rich food. However, the umami taste may not always
be recognized by the western population and including the
measurement of the umami threshold together with the other
primary tastes may be confusing for participants [22]. Finally,
although sweet milk-based ONS andmore sour-like juice- and
yoghurt-based ONS were used in the present study, the pa-
tients were not asked regarding the perceived intensity of
sweetness, sourness, saltiness, and bitterness of the ONS.
Information concerning the basic orientation of the ONS
may relate to the taste function of the patients and the palat-
ability of ONS.
To conclude, a variety of types of ONS and flavours should
be offered to malnourished patients with cancer throughout
the whole treatment period, since preference is variable among
patients and the palatability of certain ONS can change over
time. Furthermore, the taste and smell function can influence
the palatability of ONS. Health care professionals should in-
form patients that the palatability of ONS can change over
time and regular structured contact between health care
professionals and patients regarding the choice of ONS is
warranted.
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